Field report SW-98 / N6 · sheet /macro
Boardroom MacroFiled from the territory
Kennedy urges GOP action on drug pricing after two-year lapse
Republican Sen. John Kennedy says two years of GOP control yielded “zero, zilch” on drug prices and urges renewed bipartisan action on PBM reform after a December 2024 bill failed.
- Grid
- SW-98 / N6
- Surveyed
- November 18, 2026
- Reading
- 4 min read
- Correspondent
- Priya Raman

Field notes
- After two years in control, Kennedy said Republicans had done “zero, zilch” on prescription-drug pricing legislation.
- A bipartisan PBM and pharmaceutical-middleman reform bill nearly passed in December 2024 but did not become law.
- Kennedy urged the Senate’s new Democratic majority to pursue “bite-sized” bipartisan legislation before Medicare for All.
- Senate Majority Leader John Thune declined to bring PBM legislation to the Senate floor.
- Kennedy previously faulted Thune for not bringing the SAVE America Act election-integrity bill to the floor before the elections.
By Priya Raman
Republican Sen. John Kennedy of Louisiana delivered a blunt verdict on Tuesday: after two years of his party controlling the Senate during the Trump presidency, it had done “zero, zilch” on legislation to lower prescription drug prices. His opening demand was action on a bipartisan bill, not another delay.
Will a bipartisan route still work?
At a Senate Judiciary Committee hearing on competition and transparency, Kennedy focused on pharmacy benefits managers (PBMs), the intermediaries in the pharmaceutical supply chain. The hearing examined how competition and transparency could put downward pressure on prices, including the role of PBMs and other drug-industry middlemen.
Addressing PBMs and other pharmaceutical intermediaries has attracted bipartisan attention for several years, yet no legislation has passed. “I’m embarrassed that my side has been in control for two years and we’ve done nothing, zero, zilch,” Kennedy said. His criticism targeted the lack of movement, not the absence of a negotiated policy path.
Kennedy pointed to a bipartisan PBM and pharmaceutical-middleman reform bill that nearly passed in December 2024. He said President Donald Trump squashed it before taking office the following January, turning what he regarded as a viable opening into a missed opportunity. “We’re not going to have another chance. We took our shot and we missed,” he said.
What route should Democrats take?
Kennedy’s immediate preference was incremental reform rather than an immediate move to a single-payer system. During the hearing, Democrats discussed how implementing a single-payer Medicare for All plan (one public payer for the population) could lower drug costs. Kennedy said he hoped the Senate’s new Democratic majority would “start in bite-sized pieces with legislation” on a bipartisan basis first.
He also warned colleagues against rushing into the broader model. “I know my colleagues on the Democratic side are hellbent for leather to try [Medicare for All], but I would encourage them, before they do that, to try to deal with this issue,” he said. The sequence matters: address PBM reform and other intermediaries while bipartisan support exists, then consider wider structural change.
Can the Senate overcome its own procedures?
Kennedy indirectly criticized Senate Majority Leader John Thune of South Dakota for declining to bring PBM legislation to the Senate floor, where bills are debated and voted on. His concern extended beyond the bill itself to the Senate’s decision-making rules.
“If I could change one rule in the United States Senate, it would be that one person should not have the power to decide what the United States Senate can consider on the floor of the United States Senate,” he said. “It’s not right.” The remark placed the burden for action on leadership that controls floor business.
The political incentives around Kennedy have sharpened. After Democrats won a landslide in the midterm elections, he has become increasingly critical of the Trump administration and Republican leadership. He is also speculated to be among a crowded field of potential 2028 GOP presidential candidates.
That pressure has a record. Kennedy previously chided Thune for failing to bring the SAVE America Act, an election-integrity bill, to the Senate floor before the elections. The earlier complaint and his current one concern the same operating problem: one leader’s decision can leave an available bill without a floor vote.
What would action require now?
Kennedy’s case rests on a narrow mechanism: target the roles of PBMs and other pharmaceutical intermediaries, use competition and transparency to constrain pricing, and pass reforms in steps that Republicans and Democrats can support. The immediate test is procedural, because Kennedy says another opening may not arrive.
The reported call for action included no price target, savings estimate or timetable. That leaves the hearing focused on political direction rather than measurable financial outcomes, while the strategic alternative is to wait for Medicare for All, a choice Kennedy urged Democrats not to make before exhausting bipartisan action.
The decision Kennedy is pressing is whether to revive a narrow bipartisan bill now, while a Democratic majority exists, or let another attempt lapse. His warning is blunt: the December 2024 near-passage showed that Republican and Democratic support can coexist, but leadership decisions and Senate rules may still prevent agreement from becoming law.
via washingtonexaminer.com (Source)
More from Priya Raman
Show full bio
Senior reporter covering technology and product news in corporate strategy and chief-executive leadership at CEO Frontier.
460 articles
Adjacent sheets
- Democrats Won Congress. Now They Must Rebuild Trade Policy
- Thune Weighs Pre-Thanksgiving Push to Advance $350 Billion Pentagon Funding
- Democrats Won the Midterms. Trump's Tariffs Will Survive Anyway
- Senators Demand HHS Action on Prediction Markets Tied to Drug Trials
- Senate Republicans Turn on Commerce Secretary Lutnick Over Nvidia Chips